Gilead Sciences: Phase 3 trial shows significantly greater clinical improvement on 5-day Remdesivir treatment
|Gilead Sciences announced the results from the phase three trial of Remdesivir in patients with moderate COVID-19 infection. Below are key takeaways, as reported by Reuters.
"Phase 3 trial demonstrates a 5-day treatment course of Remdesivir resulted in significantly greater clinical improvement vs standard of care alone."
"Remdesivir was generally well-tolerated in both 5-day and 10-day treatment groups."
"Non-statistically significant increases in clinical worsening/death observed in the standard of care only group compared with Remdesivir groups."
"Study demonstrated that patients in the 5-day Remdesivir treatment group were 65% more likely to have clinical improvement at day 11."
"Odds of improvement in clinical status with a 10-day course of Remdesivir were trending toward but not reaching statistical significance."
"Gilead Sciences Inc plans to submit full data from phase 3 simple trial of Remdesivir for publication in a peer-reviewed journal in coming weeks."
"At day 11, more proportion of patients in the 5-day group of Remdesivir met improvement in clinical status vs standard of care group."
"No new safety signals were identified with Remdesivir across either treatment group."
Market reaction
This statement doesn't seem to be having a significant impact on market sentiment. As of writing, the S&P 500 futures were down 0.23% on a daily basis.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.